INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On May1, 2017, Innoviva, Inc., a Delaware corporation (the
Company), filed a Brief in Support of its Cross Motion for a
Status Quo Order Confirming the Directors of Innoviva Pending
Resolution of the Section225 Action and in Opposition to
Plaintiffs Motion for Entry of Status Quo Order in the Delaware
Court of Chancery in connection with previously disclosed case
captioned Sarissa Capital Domestic Fund LP, et al. v.
Innoviva,Inc., C.A. No.2017-0309-JRS (Del. Ch. April20,
2017). On April30, 2017,the Company also filed a Brief in Support
of its Motion to Dismiss the Verified Complaint, as corrected on
May 1, 2017, in the Delaware Court of Chancery in connection with
previously disclosed case captioned Sarissa Capital Domestic
Fund LP, et al. v. Innoviva,Inc., C.A. No.2017-0309-JRS
(Del. Ch. April20, 2017). A copy of each of Defendant
Innoviva,Inc.s Brief in Support of its Motion to Dismiss the
Verified Complaint and Defendant Innoviva,Inc.s Brief in Support
of its Cross Motion for a Status Quo Order Confirming the
Directors of Innoviva Pending Resolution of the Section225 Action
and in Opposition to Plaintiffs Motion for Entry of Status Quo
Order are furnished herewith as Exhibit99.1 and Exhibit99.2,
respectively, to this Current Report on Form8-K and are
incorporated herein by reference.

The information furnished to Item 7.01 of this Current Report on
Form8-K and in each of Exhibit99.1 and Exhibit99.2 shall not be
deemed to be filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), is not
subject to the liabilities of that section and is not deemed
incorporated by reference in any filing of the Companys under the
Securities Act of 1933, as amended, or the Exchange Act, except
as otherwise expressly stated in such filing or document.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

About INNOVIVA, INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

INNOVIVA, INC. (NASDAQ:INVA) Recent Trading Information

INNOVIVA, INC. (NASDAQ:INVA) closed its last trading session up +0.47 at 12.25 with 1,269,558 shares trading hands.